knowledge
SAN DIEGO — U.S. legislation that seeks to restrict American biotechs from working with certain Chinese firms and suppliers is for now just that — a proposal, not a law. But the looming bill’s impact was clearly visible at this year’s meeting of the industry’s largest trade group.
A number of biotech companies in attendance at the meeting of the Biotechnology Innovation Organization told STAT they’re actively looking to strike deals with U.S.-based drug manufacturers rather than companies named in the legislation, even though doing so will be more costly. An executive at a U.S.-based contract development and manufacturing organization, or CDMO, who spoke on condition of anonymity, said that “month to month, new business has gone through the roof.”
advertisement
Meanwhile, some Chinese suppliers not named in the bill are paradoxically drawing increased interest from biotechs — while hearing from some customers worried those manufacturers could be blacklisted in the future.
STAT+ Exclusive Story
Already have an account? Log in
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account? Log in
Already have an account? Log in
Monthly
$39
Totals $468 per year
$39/month Get StartedTotals $468 per year
Starter
$30
for 3 months, then $39/month
$30 for 3 months Get StartedThen $39/month
Annual
$399
Save 15%
$399/year Get StartedSave 15%
11+ Users
Custom
Savings start at 25%!
Request A Quote Request A QuoteSavings start at 25%!
2-10 Users
$300
Annually per user
$300/year Get Started$300 Annually per user
View All Plans
Get unlimited access to award-winning journalism and exclusive events.
Subscribe Log InNext article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
